The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants

Oncogene

Volumn 34, Issue 9, 2015, Pages 1126-1140

  Buss, M C ^a   Remke, M ^b   Lee, J ^a   Gandhi, K ^a   Schniederjan, M J ^a   Kool, M ^c   Northcott, P A ^c   Pfister, S M ^c,d   Taylor, M D ^b   Castellino, R C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR KINASE 5; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; CXCL2 CHEMOKINE; CXCL2 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; GRK5 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE 2C;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CEREBELLUM; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; WIP1 GENE; ANIMAL; CANCER TRANSPLANTATION; CEREBELLUM TUMOR; GENETICS; INFANT; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; SCID MOUSE; TUMOR CELL LINE; YOUNG ADULT;

MUS;

ADOLESCENT; ANIMALS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CHEMOKINE CXCL2; CHILD; CHILD, PRESCHOOL; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 5; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEIN PHOSPHATASES; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84930247737     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.37     Document Type: Article

References (69)

1. McNeil DE, Cote TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 2002;39:190-194.
2. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE et al. Riskadapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-820.
3. Dhall G. Medulloblastoma. J Child Neurol 2009;24:1418-1430.
4. Von Hoff K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 2009;45:1209-1217.
5. Mabbott DJ, Spiegler BJ, Greenberg ML, Rutka JT, Hyder DJ, Bouffet E. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 2005;23:2256-2263.
6. Belza MG, Donaldson SS, Steinberg GK, Cox RS, Cogen PH. Medulloblastoma: freedom from relapse longer than 8 years-a therapeutic cure? J Neurosurg 1991;75:575-582.
7. Torres CF, Rebsamen S, Silber JH, Sutton LN, Bilaniuk LT, Zimmerman RA et al. Surveillance scanning of children with medulloblastoma. New Engl J Med 1994;330:892-895.
8. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123:465-472.
9. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012;123:473-484.
10. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488:106-110.
11. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011;29:1400-1407.
12. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-1414.
13. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011;121:381-396.
14. Gessi M, Von Bueren AO, Rutkowski S, Pietsch T. p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol 2011;106:135-141.
15. Sengupta R, Dubuc A, Ward S, Yang L, Northcott P, Woerner BM et al. CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res 2012;72:122-132.
16. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-574.
17. Gajjar AJ, Stewart CF, Ellison DW, Curran T, Phillips P, Goldman S et al. A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent of refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25). J Clin Oncol 2010;28:18s.
18. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T et al. Subgroupspecific structural variation across 1000 medulloblastoma genomes. Nature 2012;488:49-56.
19. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29:1424-1430.
20. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, Van Sluis P et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008;3:e3088.
21. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002;31:210-215.
22. Nannenga B, Lu X, Dumble M, Van Maanen M, Nguyen TA, Sutton R et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog 2006;45:594-604.
23. Li J, Yang Y, Peng Y, Austin RJ, Van Eyndhoven WG, Nguyen KC et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002;31:133-134.
24. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003;63:1876-1883.
25. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 2008;86:245-256.
26. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005;23:8853-8862.
27. Buss MC, Read TA, Schniederjan MJ, Gandhi K, Castellino RC. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol 2012;14:440-458.
28. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011;29:2717-2723.
29. Siu IM, Lal A, Blankenship JR, Aldosari N, Riggins GJ. c-Myc promoter activation in medulloblastoma. Cancer Res 2003;63:4773-4776.
30. Pfister S. Medulloblastoma: a potpourri of distinct entities. Acta Neuropathol 2012;123:463-464.
31. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003;100:13513-13518.
32. Woerner BM, Warrington NM, Kung AL, Perry A, Rubin JB. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 2005;65:11392-11399.
33. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848.
34. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-241.
35. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321-1328.
36. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009;15:441-453.
37. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol 2010;3:1-12.
38. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012;482:529-533.
39. Barker BL, Benovic JL. G protein-coupled receptor kinase 5 phosphorylation of hip regulates internalization of the chemokine receptor CXCR4. Biochemistry 2011;50:6933-6941.
40. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-1636.
41. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006;5:2666-2670.
42. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004;10:5482-5493.
43. Pan E, Pellarin M, Holmes E, Smirnov I, Misra A, Eberhart CG et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005;11:4733-4740.
44. Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, Northcott PA et al. Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 2010;70:8003-8014.
45. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997;94:6048-6053.
46. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H et al. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000;19:6517-6526.
47. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007;12:342-354.
48. Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 2006;23:757-764.
49. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005;19:1162-1174.
50. Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ 2006;13:1170-1180.
51. Yoda A, Xu XZ, Onishi N, Toyoshima K, Fujimoto H, Kato N et al. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J Biol Chem 2006;281:24847-24862.
52. Demidov ON, Timofeev O, Lwin HN, Kek C, Appella E, Bulavin DV. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell 2007;1:180-190.
53. Pandolfi S, Montagnani V, Penachioni JY, Vinci MC, Olivito B, Borgognoni L et al. WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function. Oncogene 2012;32:4737-4747.
54. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007;26:2502-2506.
55. Kleiblova P, Shaltiel IA, Benada J, Sevcik J, Pechackova S, Pohlreich P et al. Gain-offunction mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol 2013;201:511-521.
56. Dudgeon C, Shreeram S, Tanoue K, Mazur SJ, Sayadi A, Robinson RC et al. Genetic variants and mutations of PPM1D control the response to DNA damage. Cell Cycle 2013;12:2656-2664.
57. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2013;493:406-410.
58. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94.
59. Klein RS, Rubin JB, Gibson HD, De Haan EN, Alvarez-Hernandez X, Segal RA et al. SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development 2001;128:1971-1981.
60. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, De Vries EG et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer 2013;49:219-230.
61. Bian XW, Yang SX, Chen JH, Ping YF, Zhou XD, Wang QL et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007;61:570-578 (discussion 578-579).
62. Calatozzolo C, Maderna E, Pollo B, Gelati M, Marras C, Silvani A et al. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 2006;5:827-832.
63. Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 1998;38:289-319.
64. Orsini MJ, Parent JL, Mundell SJ, Marchese A, Benovic JL. Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem 1999;274:31076-31086.
65. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-1113.
66. Rao G, Pedone CA, Coffin CM, Holland EC, Fults DW. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia 2003;5:198-204.
67. Mumert M, Dubuc A, Wu X, Northcott PA, Chin SS, Pedone CA et al. Functional genomics identifies drivers of medulloblastoma dissemination. Cancer Res 2012;72:4944-4953.
68. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 2011;29:3852-3861.
69. Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM et al. Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer 2007;7:127.